This single unified policy shall prohibit hedging transactions for shares subject to this policy which are not sales but reduce the risk of loss to the executive. Otherwise our directors might be able to avoid the impact of this proposal. This policy shall supplement any other share ownership requirements that have been established for senior executives, and should be implemented without violating current company contractual obligations or the terms of any current pay or benefit plan. The Board is encouraged to obtain waivers of any current pay or benefit plan for senior executives that might delay implementation of this proposal. Requiring senior executives to hold a significant portion of stock obtained through executive pay plans would focus our executives on our company?s long-term success. A Conference Board Task Force report stated that hold-to-retirement requirements give executives ?an ever-growing incentive to focus on long-term stock price performance.? Now could be good timing to make sure executives retain significant stock since Revvity stock was at $203 in 2021 and fell to $91 in late 2025 despite a robust stock market. It is also important to make sure executives retain significant stock given these unfavorable news reports: Revvity faced consistent pressure on its operating margins. This has been attributed to lower volumes of high-margin diagnostic tests, unfavorable product mix, and tariff impacts, raising questions about Revvity?s ability to maintain profitability. The Diagnostics segment faced significant headwinds in China, with sales declining due to changes in hospital lab reimbursement policies (specifically, Diagnosis-Related Groups or DRGs). Hospitals shifted from Revvity's higher-value multiplex tests to lower-priced alternatives, resulting in a meaningful pullback in Immunodiagnostics business. The academic and government customer segment continued to show weakness, with revenue declining in the low single digits year over year. Analysts raised questions about Revvity?s ability to maintain profitability while investing in growth, and have noted Revvity stock carried a Zacks Rank #4 (Sell) at one point. Revvity Health Sciences is facing a lawsuit from more than two dozen marijuana testing laboratories seeking $1 billion in damages. The suit accuses Revvity of a "knowingly and intentionally deceptive marketing and sales campaign" to sell equipment that was not designed to test cannabis effectively.